Ftse Mib
33.577,42
-0,39%
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
60.802,36
-1,63%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Bicycle Therapeutics PLC (BCYC) Bicycle Therapeutics PLC (BCYC) Notizie

BCYC

Bicycle Therapeutics (BCYC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCYC
DataOraFonteTitoloSimboloCompagnia
18/06/202422:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCYCBicycle Therapeutics PLC
18/06/202422:14Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BCYCBicycle Therapeutics PLC
03/06/202413:00Business WireBicycle Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202423:05Business WireBicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
23/05/202413:00Business WireBicycle Therapeutics Announces $555 Million Private Placement Equity FinancingNASDAQ:BCYCBicycle Therapeutics PLC
02/05/202413:00Business WireBicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
24/04/202416:05Business WireBicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingNASDAQ:BCYCBicycle Therapeutics PLC
02/04/202413:00Business WireBicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
05/03/202422:35Business WireBicycle Therapeutics to Present at the AACR Annual Meeting 2024NASDAQ:BCYCBicycle Therapeutics PLC
21/02/202422:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
21/02/202422:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
20/02/202414:38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCYCBicycle Therapeutics PLC
20/02/202413:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BCYCBicycle Therapeutics PLC
20/02/202413:05Business WireBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:BCYCBicycle Therapeutics PLC
14/02/202422:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCYCBicycle Therapeutics PLC
07/02/202413:00Business WireBicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
03/01/202422:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCYCBicycle Therapeutics PLC
14/12/202313:00Business WireBicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D DayNASDAQ:BCYCBicycle Therapeutics PLC
30/11/202313:00Business WireBicycle Therapeutics to Host R&D Day on December 14NASDAQ:BCYCBicycle Therapeutics PLC
02/11/202312:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCYCBicycle Therapeutics PLC
02/11/202312:00Business WireBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D DayNASDAQ:BCYCBicycle Therapeutics PLC
19/10/202313:00Business WireBicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder CancerNASDAQ:BCYCBicycle Therapeutics PLC
19/10/202310:00GlobeNewswire Inc.Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive DirectorNASDAQ:BCYCBicycle Therapeutics PLC
11/09/202317:08Dow Jones NewsBicycle Therapeutics Shares Rise 8% After Continuation of BT8009 DevelopmentNASDAQ:BCYCBicycle Therapeutics PLC
11/09/202313:00Business WireBicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder CancerNASDAQ:BCYCBicycle Therapeutics PLC
05/09/202313:00Business WireBicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:BCYCBicycle Therapeutics PLC
03/08/202312:59Business WireBicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:BCYCBicycle Therapeutics PLC
18/07/202313:00Business WireBicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:BCYCBicycle Therapeutics PLC
13/07/202322:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCYCBicycle Therapeutics PLC
13/07/202304:23Business WireBicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary SharesNASDAQ:BCYCBicycle Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCYC

La tua Cronologia

LSE
MRP
Meridian Petroleum
KOSPI
005070
Cosmo AM and T
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network